Granules India Limited, in partnership with the National Institute of Pharmaceutical Education and Research (NIPER), S.A.S Nagar, today inaugurated the Dr. Chigurupati Centre of Excellence in Innovative and Sustainable Pharmaceutical Development (CCE-ISPD). This Granules’ CSR initiative aims to empower students and researchers with access to cutting-edge facilities and resources, fostering innovation in eco-friendly solutions for learning pharmaceutical manufacturing.

Granules India Ltd., a vertically integrated pharmaceutical company, today announced its financial results for the quarter and financial year ended March 31, 2025.

EcoVadis is one of the world’s trusted providers of business sustainability ratings, assessing companies on environment, labour & human rights, ethics, and sustainable procurement. This recognition affirms Granules India’s robust sustainability practices and transparency in its business operations.

The Indian subsidiary, Granules Peptides Private Limited, acquired 100% of the equity of Senn Chemicals from the founding Senn family.

Granules India announced the signing of the acquisition agreement regarding Senn Chemicals AG, a Swiss-based CDMO specialising in peptides

Granules India received approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA)

Granules received validation and approval from the Science Based Targets initiative (SBTi) for its near-term, long-term, and net-zero goals

Mr. Sarmad will provide expert guidance on sustainability, climate policy, and environmental initiatives at Granules India Limited